Merck & Co Puts A Date On Spinning Off Biosimilars

Plans Have Been Public For 12 Months

 
• By Dean Rudge

Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.

Spinning top
The Merck spin-off Organon will take residence in New Jersey. • Source: Shutterstock

More from Biosimilars

More from Products